Methods:
A subanalysis of the investigator-assessed severe subjects from a Phase 3, investigator-blinded, randomized study comparing IVM 1% once daily (QD) with MTZ 0.75% twice daily (BID) over 16 weeks followed by a 36-week extension period was performed. Efficacy assessments were Dermatology Life Quality Index (DLQI) and EuroQol-5 Dimension (EQ-5D) questionnaires, investigator's global assessment (IGA), subject assessment of rosacea improvement, and inflammatory lesion counts. Adverse events (AEs) were monitored throughout the study.
Results: A total of 161 subjects (16.7% of overall study population; 80 IVM 1% and 81 MTZ 0.75%) had an IGA score of 4 at baseline representing severe papulopustular rosacea.
Significantly more IVM 1% subjects had a minimal clinically important difference (MCID, defined as a decrease from baseline of C4 points) in DLQI score than MTZ 0.75% subjects at week 16 (65.4% vs. 39.2%; P = 0.001) and week 52 (68.8% vs. 40.4%; P = 0.003). At week 16, the mean EQ-5D score for the IVM 1% subjects was higher (better 63.0%; P = 0.005). Incidence of AEs was comparable between groups. Conclusion: Better efficacy with IVM 1% cream (QD) compared to MTZ 0.75% cream (BID) contributes to an improved quality of life with significantly more patients achieving an MCID in DLQI score at week 16 and higher mean EQ-5D score. IVM 1% cream is thus a better alternative than MTZ 0.75% cream for severe papulopustular rosacea patients. 
INTRODUCTION
Rosacea is a chronic inflammatory disease that affects around 10% of the population in Europe [1] . Clinical characteristics include primary features (transient erythema or flushing, fixed/ non-transient erythema, inflammatory papules/pustules, telangiectasia) and secondary features (burning, plaque, edema) in various combinations [2] . As it is readily visible on the face, rosacea has a considerable impact on a patient's quality of life (QoL) [3] .
Until recently, patients with severe inflammatory lesions were often treated with antibiotics. However, a European Commission action plan [4] 
METHODS

Study Design and Subjects
This was a post hoc subanalysis of a Phase 3, investigator-blinded, randomized, parallel-group, superiority study that previously compared the This post hoc subgroup analysis was performed on study subjects with severe papulopustular rosacea, i.e., an investigator's global assessment (IGA) score (see Table 1 ) of 4 at baseline.
Treatment
As previously described, subjects were randomized in a 1:1 ratio to receive either were monitored throughout the study.
Statistical Methods
The means of the DLQI total score and EQ-5D
index were calculated using the definitions for each questionnaire.
The EQ-5D descriptive system consists of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with three levels each (no problems, some problems, and extreme problems).The EQ-5D results were converted into a single summary index (where 0 = dead and 1.0 = full health) by applying Dutch preference weights [12] . An improvement in the EQ-5D score of C0.074 vs. baseline is considered as the minimal clinically important difference (MCID) [13] .
The 10 DLQI questions had four possible responses from not at all (0) to very much (3) [11] and the total score was calculated by summing the score of each question; the maximum score is 30 (extremely large effect on patient's life) and minimum is 0 (no effect on patient's life). The 10 questions cover 6 domains and DLQI subscale scores were calculated for symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The changes from 
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RESULTS
Subject Disposition
Of the total of 962 randomized subjects (478 IVM 1%, 484 MTZ 0.75%), 161 (16.7%; 80 IVM 1%, 81 MTZ 0.75%) had an IGA score of 4 at baseline representing severe inflammatory lesions of rosacea.
Quality of Life
In this subgroup of 161 subjects with severe inflammatory lesions of rosacea, the mean DLQI total scores at baseline were 7.8 and 6.6
for the IVM 1% and MTZ 0.75% groups, respectively, indicating a moderate impact of severe papulopustular rosacea on QoL.
At week 16, a greater reduction from baseline (i.e., a greater improvement in QoL) in the mean DLQI score was observed for IVM 1% group subjects than MTZ 0.75% subjects (-6.0 vs. -3.8; P = 0.014). Similar results were observed at week 52 (-6.0 vs. -4.8; P = 0.010; Fig. 1 The greatest improvement in the mean score between baseline and week 16 was observed for the DLQI subscale of symptoms and feelings with a mean score of -2.2 for the IVM 1% group and -1.6 for the MTZ 0.75% group (P = 0.03). group and the MTZ 0.75% group, respectively (Fig. 2) . Similarly, at week 52, the mean change from baseline was significantly higher for IVM 1% subjects than MTZ 0.75% subjects (0.103 vs. 0.084; P = 0.010). Subjects with IGA success (grade 0-1) consistently had statistically significantly better EQ-5D scores than subjects with IGA failure (grade 2-4; 0.939 ± 0.131 vs.
0.870 ± 0.172; P\0.01).
The most improved EQ-5D dimensions were pain/discomfort and anxiety/depression. The number of subjects without pain/discomfort was 22.1% higher in the IVM 1% group at week 16 compared to baseline, whereas the respective increase was only 5.9% in the MTZ 0.75% group.
Efficacy
For success rate based on an IGA score of 0 or 1 at week 16, more subjects in the IVM 1% group (66/80 subjects, 82.5%) were assessed as success compared to the MTZ 0.75% group (51/81 subjects, 63.0%), i.e., a between-group difference of 19.5% (Fig. 3) .
At week 16, twice as many IVM 1% subjects (22/80 subjects, 27.5%) than MTZ 0.75% subjects (10/81 subjects, 12.3%) had an IGA score of 0 (clear; Fig. 3 ). At week 16, the mean (median) percentage reduction in inflammatory lesion counts from baseline (intent-to-treat last observation carried forward) was higher for the IVM 1% group at Subjects' rating of rosacea improvement is illustrated in Fig. 4 . Patient self-assessment of rosacea improvement at week 16 was good/ excellent for 85.9% of IVM-treated subjects vs.
67.5% of MTZ-treated subjects. Similarly, at week 52, 93.7% of subjects in the IVM 1% group rated their improvement as good/ excellent compared to 77.5% in the MTZ 0.75% group. The overall success rate, i.e., percentage of subjects who were successfully treated over the treatment period of 16 weeks (IGA 0 or 1) and never relapsed during the 36-week extension period, was higher in the IVM 1% group than the MTZ 0.75% group (23.2% IVM 1% vs. 12.3% MTZ 0.75%).
Safety
There were a total of three related adverse events in Part A (rosacea in 1 IVM 1% subject; allergic dermatitis in 1 MTZ 0.75% subject; pruritus in 1 MTZ 0.75% subject) and two related adverse events in Part B (pruritus and rosacea in 1 IVM 1% subject).
DISCUSSION
The greater improvement in QoL in the IVM 1% group than in the MTZ 0.75% group reflects the superior efficacy with IVM 1% with a comparable safety profile in this subpopulation of patients with severe inflammatory lesions of rosacea. Although QoL is inherently subjective in nature, the importance of patient-reported outcomes in evaluating the efficacy and safety of treatments for rosacea was highlighted in the 2015 Cochrane review with ''Change in quality of life'' being a primary outcome measure [6] . It is important to determine whether changes in physical symptoms interpreted by the clinician translate into measurably significant changes in QoL for the individual. This was the case since mean difference in DLQI scores and EQ-5D scores were consistently statistically significantly better for patients with treatment success than for those with treatment failure. Since the extent of improvement in QoL total scores lack a direct clinical meaning, the concept of MCID (defined previously [13, 14] ) was used to confirm clinically relevant treatment effectiveness.
More subjects in the IVM 1% group had an MCID in DLQI score compared with the MTZ 0.75% group at week 16 (65.4% vs. 39.2%; P = 0.001). As all patients who continued into Part B had been treated successfully in Part A whatever the treatment group (i.e., all were IGA 0 or 1 at week 16), it may be expected that the subjects in both groups would be equally satisfied with the treatment in Part B.
However, this was not the case since at week 52, the improvement in proportion of subjects with an MCID in DLQI score (68.8% IVM 1% vs.
40.4% MTZ 0.75%; P = 0.003) was again significantly greater in the IVM 1% group, reflecting the clinical superiority of IVM 1% over the long-term. These results were corroborated with the results obtained using the generic EQ-5D questionnaire, with which the mean change from baseline at week 16 and week 52 were significantly higher in the IVM 1% group than the MTZ 0.75% group. The EQ-5D is a very widely used generic questionnaire and it is unusual to observe a statistically significant difference in scores for dermatological diseases, especially with a small sample size.
QoL data collected at week 32 could not be directly compared between the IVM 1% and MTZ 0.75% groups as the level of exposure to the two drugs was heterogeneous at this time point. In fact, more subjects in the MTZ 0.75% group had already been re-treated at week 32 compared to the IVM 1% group due to the longer remission time for the IVM 1% group, as reported previously [9] .
In this subanalysis of severe patients, the success rate at week 16 was higher in the IVM-treated group than in the MTZ-treated group (82.5% vs. 63% IGA 0 or 1; P = 0.005).
The superiority of IVM 1% was more pronounced in this subpopulation of severe subjects (between-group difference of 19.5%) than in the overall population of moderate-to-severe subjects, in which the success rate was reported to be 84.9% IVM 1% vs. 75.4% MTZ 0.75% at week 16 (P\0.001; between-group difference of 9.5%) [8] .
Archive photographs are shown in Fig. 5 to illustrate a severe subject (IGA of 4 at baseline)
who had an IGA of 1 after 14 weeks treatment At week 52, the overall success rate of subjects who never relapsed was higher in the IVM 1% group than the MTZ 0.75% group (23.2% IVM 1% vs. 12.3% MTZ 0.75%), which is important from a pharmacoeconomic perspective, in addition to the fact that IVM 1% is QD and so requires a lower quantity of product per treatment compared to MTZ 0.75% (BID).
Comparable safety results demonstrated that both products were very well tolerated, which is important as rosacea patients tend to have highly sensitive skin. The results in this group of severe subjects are consistent with a previous long-term safety study on IVM 1% cream in moderate-to-severe subjects [15] . Severe inflammatory lesions of rosacea are often treated with oral antibiotics, particularly tetracyclines, despite a poor safety profile [6, 16] . However, antibiotic resistance is now a major threat to public health causing people to be sick for longer and increasing the cost of health care with lengthier stays in hospital [5] .
Dermatologists contribute to overall antibiotic use and tend to prescribe antibiotics chronically, particularly for acne and rosacea [17] . Hence, there is a need to find effective alternatives to antibiotics or sub-anti-microbial dosage forms. One such example is the use of a sub-anti-microbial dosage of doxycycline (40 mg modified-release doxycycline), which has anti-inflammatory rather than
anti-microbial effect, that has been reported to be as effective as 100 mg with significantly fewer gastrointestinal side effects [18] . Since ivermectin is a member of the avermectin class of compounds (with anti-inflammatory and anti-parasitic effects) and is not an antibiotic, it is thus an effective alternative treatment for papulopustular rosacea, even in severe patients. Limitations of this subanalysis include the small number of subjects. However, despite the small sample size, statistical significance was reached for the efficacy endpoints. Another limitation was the absence of double-blind due to the fact that IVM 1% is QD, whereas MTZ 0.75% is BID, as well as the obvious difference in appearance of the two creams. However, a QD treatment has the advantage of being more appealing to patients, especially when it is more efficacious.
CONCLUSIONS
In patients with severe papulopustular rosacea, 
